Telix Pharmaceuticals (TLX) Accumulated Expenses (2023 - 2024)
Telix Pharmaceuticals (TLX) posted quarterly Accumulated Expenses of $33.7 million for Q4 2024, up 5211.57% year-on-year from $634896.0 in Q1 2024, and up 5211.57% on a QoQ basis from $634896.0 in Q4 2023.
Telix Pharmaceuticals (TLX) Accumulated Expenses (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Accumulated Expenses for 2 consecutive years, with $33.7 million the latest figure, recorded in Q4 2024.
- Quarterly Accumulated Expenses rose 5211.57% year-over-year to $33.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $33.7 million (up 5211.57% YoY) and the FY2024 annual result came in at $33.7 million, up 5211.57% from the prior year.
- Accumulated Expenses improved to $33.7 million in Q4 2024 per TLX's latest filing, from $634896.0 in the prior quarter.
- Over the last five years, Accumulated Expenses for TLX reached as high as $33.7 million in Q4 2024 and fell as low as $634896.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Telix Pharmaceuticals | 3.55 Bn | 3.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 33.72 Mn |
| Dec 31, 2023 | 634,895.98 |